03/05/2019 Transcatheter Heart Valves Greece 2019 | K. Papadopoulos | Lessons from the MITRA-FR and COAPT studies; How should we quantify MR?

info_icon

 

Δηλώνω υπεύθυνα ότι είμαι γιατρός ή εξασκώ παραϊατρικό επάγγελμα |

I hereby declare that I am a medical professional  

 

Συμφωνώ | Άκυρο

871 VIEWS EXPANDCOLLAPSE

Share

115,795 total
707 live
871 video
55,497 photo
Views:

3/5Αίθουσα Banquet Hall, MAICC -
18:30-20:00 JOINT SESSION II
Πρόεδροι: G. Athanassopoulos,G. Giamouzis,A. Trikas
18:30-18:45 Exercise-stress echocardiography and effort intolerance in asymptomatic/symptomatic degenerative mitral regurgitation
D. Klettas
18:45-19:00 Mitraclip vs. PASCAL. Similarities and differences
K. Spargias
19:00-19:15 Lessons from the MITRA-FR and COAPT studies; How should we quantify MR?
K. Papadopoulos
19:15-19:30 Percutaneous mitral repair after failed open surgery
S. Kar
19:30-19:45 Who are the best candidates for experimental TMVR in 2019?
N. Kleiman
19:45-20:00 Lessons from an International Registry on Transcatheter Tricuspid Thearapies
F. Maisano


Το 8o Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών Βαλβιδοπαθειών θα μεταδοθεί ζωντανά στο Livemedia
3 - 4 Μαίου 2019. Το Συνέδριο διοργανώνεται από το Διαγνωστικό Θεραπευτήριο Κέντρο Αθηνών Υγεία και θα πραγματοποιηθεί στο Μέγαρο Μουσικής Αθηνών.

Για περισσότερες πληροφορίες πατήστε εδώ.

 
Sort by Date | Views
G. Pattakos | Latest TAVR Randomized Trials... 788
M. Vavuranakis | High-Quality TAVR: Does... 759
S. Prapas | The selection of SAVR devices... 797
P. Dedeilas | Rapid Deployment Surgical... 768
WELCOME NOTES 752
A. Chalapas | CT Imaging of Bicuspid Aortic... 775
N. Van Mieghem | TAVR will be the treatment... 855
D. Angouras | Most Bicuspid aortic valves... 747
S. Kodali | Strokes After TAVR and SAVR:... 717
R. Mehran | What’s Holding Back Cerebral... 717
M. Οto | TAVR in the patient with significant... 697
A. Halapas | Live in a Box | TAVR Session... 735
L. Papavasileiou | Incidence, predictors... 766
N. Kleiman | Is paravalvular regurgitation... 701
S. Kapadia | A Selective versus Routine... 697
M. Οto | Management of Coronary Disease... 711
M. Chirssoheris | Live in a Box | TAVI Session... 707
A. Katsaros | Impact of valvular heart disease... 740
A. Patrianakos | Patient-prosthesis mismatch... 728
E. Anagnostou | Moderate aortic stenosis... 889
G. Pattakos | Minimally invasive surgery... 762
S. Kodali | In hospital mortality after... 671
G. Giamouzis - G. Karatasakis | JOINT SESSON... 724
S. Kapadia | TAVR for All? New insights... 685
J. Kisslo | Defining Secondary Mitral Regurgitation:... 715
S. Kar | Mitraclip for Functional Mitral... 691
D. Klettas | Exercise-stress echocardiography... 927
K. Spargias | Mitraclip vs. PASCAL. Similarities... 795
K. Papadopoulos | Lessons from the MITRA-FR... 872
S. Kar | Percutaneous mitral repair after... 719
N. Kleiman | Who are the best candidates... 738
F. Maisano | Lessons from an International... 749
M. Chrissoheris | Echocardiographic evaluation... 739
A. Pitsis | Mitral Valve-in-valve and valve-in-ring... 713
J. Velianou | Results of valve-in-MAC (mitral... 687
S. Kar | Currently enrolling TMVR and TTVR... 761
F. Maisano | You can’t beat safety and simplicity:... 732
N. Baikoussis - K. Bellos - E. Petropoulou... 712
K. Papadopoulos | Live in a box Mitraclip... 699
V. Voudris | A growing conundrum: Coronary... 703
N. Van Mieghem | Mechanisms of coronary... 694
N. Bouboulis | Hybrid beating heart bypass... 692
A. Manginas | Guidelines and classification... 724
R. Mehran | TAVR plus/minus AFib and/or... 719
G. Dangas | The Spectrum of Leaflet Thrombosis... 687
Discussion | TAVI Session IV – Avoiding Pitfalls 676
G. Pattakos |Live in a Box | TAVI Session... 718
M. Kasel | To crack or not to crack? The... 748
K. Spargias | Supra-annular TAVR devices.... 704
J. Velianou | To split or not to split?... 742
M. Kasel | The rapid emergence of transcaval... 645
P. Dardas | TAVR in the decompensated patient... 508
K. Dimitriadis | Transcatheter Heart Valves... 514
Discussion | TAVR Session V – Dealing with... 496
A. Οto - Transcatheter Heart Valves Greece... 513
S. Kapadia | Transcatheter Heart Valves Greece... 500
Σ.Παττακός | Transcatheter Heart Valves Greece... 483
K. Spargias | How far should we push the... 543
M. Chrissoheris | Live-in-a-box TAVR | TAVR... 524
A. Holzamer | The ACCURATE Neo TAVR system.... 500
L. Michalis | The PORTICO TAVR system. Program... 494
V. Martzaklis | Medtronic Structural Heart... 535
M. Kasel | What to expect in the near future... 471
L. Michalis | A Deep Dive Into TAVR Cost-Effectiveness... 480
M. Kasel | TAVR device selection in the... 504
J. Kisslo | Three-Dimensional Echocardiography... 515
F. Maisano | Patient selection for transcatheter... 509
M. Chrissoheris | Advanced echocardiography... 476
K. Spargias | Technical tips and tricks... 530
V. Ninios | An often Challenging MitraClip... 492
A. Tzifa | Transcatheter valve-in-valve... 549
A. Pitsis | Minimally invasive surgery for... 488
S. Pattakos | The Structural Heart and Valve... 477
C. Arampatzis | My best and/or my worst... 502
J. Iakovou | My best and/or my worst Structural... 471
G. Katsimagklis | My best and/or my worst... 492
D. Nikas | My best and/or my worst Structural... 511
K. Perreas | My best and/or my worst Structural... 488
K. Spiliotopoulos | My best and/or my worst... 495
K. Triantafyllou | My best and/or my worst... 424
D. Tsikaderis | My best and/or my worst... 483
I. Zarifis | My best and/or my worst Structural... 492
Closing of the conference 437
03/05 Banquet Hall, MAICC
09:00 - 11:00
TAVI Session I – TAVR Technology in a Rapidly-Evolving Era 

Evaluated
Evaluation
09:00 - 09:15
Latest TAVR Randomized Trials

Evaluated
Evaluation

Speaker: G. Pattakos(   )

09:15 - 09:30
High-Quality TAVR: Does a minimum volume requirement still make sense?

Evaluated
Evaluation

Speaker: M. Vavuranakis(   )

09:30 - 09:45
The selection of SAVR devices in the TAVR era

Evaluated
Evaluation

Speaker: S. Prapas(   )

09:45 - 10:00
Rapid Deployment Surgical Valves with Minimally invasive techniques. Can they compete with TAVR?

Evaluated
Evaluation

Speaker: P. Dedeilias

10:00 - 10:15
TAVR for low-risk patients with a self-expanding valve

Evaluated
Evaluation

Speaker: N. Kleiman

10:15 - 10:30
Live-in-a-box TAVR

Evaluated
Evaluation
10:45 - 11:00
Discussion

Chairmen: I. Goudevenos, J. Kanakakis, D. Sionis, P. Vardas

Commentators: S. Karagiannis, G. Makos, A. Tzikas

11:00 - 11:30
WELCOME NOTES 

Evaluated
Evaluation

Chairmen: S. Pattakos, S. Konstantinidis, I. Goudevenos, D. Tousoulis, P. Vardas, A. Kartapanis

11:30 - 13:30
TAVR Session II – TAVR on the Uprise. How do we deal with complex situations? 

Evaluated
Evaluation
12:00 - 12:10
CT Imaging of Bicuspid Aortic Valve Disease. Anatomic patterns favorable and unfavorable for TAVR and factors influencing device selection

Evaluated
Evaluation

Speaker: A. Chalapas(   )

12:10 - 12:20
TAVR will be the treatment of choice for bicuspid aortic valve disease in the future!

Evaluated
Evaluation

Speaker: N. Van Mieghem(   )

12:20 - 12:30
Most Bicuspid aortic valves (especially In younger low-risk patients) will remain in the surgical domain!

Evaluated
Evaluation

Speaker: D. Angouras(   )

12:30 - 12:40
Strokes After TAVR and SAVR: Incidence in the "Modern Era" and Key Messages

Evaluated
Evaluation

Speaker: S. Kodali(   )

12:40 - 12:50
What’s Holding Back Cerebral Embolic Protection in TAVR? Data or Money?

Evaluated
Evaluation

Speaker: R. Mehran(   )

12:50 - 13:00
TAVR in the patient with significant native or bioprosthetic mitral and/or tricuspid valve disease

Evaluated
Evaluation

Speaker: M. Οto

13:00 - 13:15
Live-in-a-box TAVR

Evaluated
Evaluation
13:15 - 13:30
Discussion

Chairmen: M. Argiriou, S. Foussas, E. Pissimisis, C. Tsioufis

Commentators: K. Aznaouridis, V. Androutsopoulou, S. Makrigiannis

13:30 - 14:00
BREAK 

14:00 - 15:45
TAVI Session III – TAVR dilemmas and complications 

Evaluated
Evaluation
14:00 - 14:15
Incidence, predictors and consequences of new LBBB and new PPM after TAVR

Evaluated
Evaluation

Speaker: L. Papavasileiou(   )

14:15 - 14:30
Is paravalvular regurgitation after TAVR still an important consideration in 2019?

Evaluated
Evaluation

Speaker: N. Kleiman(   )

14:30 - 14:45
A Selective versus Routine Minimalist Strategy. Is every patient eligible?

Evaluated
Evaluation

Speaker: S. Kapadia(   )

14:45 - 15:00
Management of Coronary Disease in AS Patients: Important Treatment Considerations (When to consider CABG, timing of PCI and TAVR, and completeness of revascularization)

Evaluated
Evaluation

Speaker: M. Οto

15:00 - 15:15
To crack or not to crack? The role for fracturing bioprosthetic valves during ViV procedures

Evaluated
Evaluation

Speaker: M. Kasel

15:15 - 15:30
Live-in-a-box TAVR

Evaluated
Evaluation
15:30 - 15:45
Discussion

Evaluated
Evaluation

Chairmen: D. Iliopoulos, G. Hahalis, V. Pyrgakis, S. Tzeis

Commentators: I. Chlorogiannis, K. Dimitriadis, A. Zacharoulis

15:45 - 16:00
Break 

Evaluated
Evaluation
16:00 - 17:30
JOINT SESSON I 

Aortic and Mitral Club

Evaluated
Evaluation
16:00 - 16:15
In hospital mortality after TAVR. Common and uncommon causes

Evaluated
Evaluation

Speaker: S. Kodali(   )